Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| High Roller Technologies, Inc.ROLR · Entity 7043 | Director | May 19, 2026 | May 21, 2026 |
| PAVmed Inc.PAVM · Entity 7317 | Director | April 01, 2021 | April 05, 2021 |
| Scopus BioPharma Inc.SCPS · Entity 133074 | Director | December 16, 2020 | December 29, 2020 |
| Streamex Corp.BSGM · Entity 1816 | Director | August 15, 2023 | August 18, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
High Roller Technologies, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2036-05-19 | Direct | 15,000 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 15,000 · Balance 15,000 F1: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on December 31, 2026. The options have a maximum term of ten (10) years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on December 31, 2026. The options have a maximum term of ten (10) years from the date of grant.
PAVmed Inc.
Report date April 01, 2021 · Filed April 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-04-01 | Direct | 50,000 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests in 12 equal quarterly installments commencing on September 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal quarterly installments commencing on September 30, 2021.
Scopus BioPharma Inc.
Report date December 16, 2020 · Filed December 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2025-12-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-12-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
Streamex Corp.
Report date August 15, 2023 · Filed August 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,999 |
Reported balance
After 2023-08-15 transaction · row 1
1 source rowRow 1 · 2023-08-15 · Grant · Acquired 16,000 · Balance 114,999 F1: The shares of restricted stock were granted in lieu of remuneration for the Company's 2023 second quarter board fees and shall be fully vested as of August 15, 2023, the date of the grant, based on a closing price of $0.6364 per share on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of restricted stock were granted in lieu of remuneration for the Company's 2023 second quarter board fees and shall be fully vested as of August 15, 2023, the date of the grant, based on a closing price of $0.6364 per share on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2026 Filed May 21, 2026 21:14 UTC | High Roller Technologies, Inc. ROLR · Entity 7043 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001753926-26-000928 · primary_doc.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-19 F1 · security: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on December 31, 2026. The options have a maximum term of ten (10) years from the date of grant. F1 · derivative.exercise_date: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on December 31, 2026. The options have a maximum term of ten (10) years from the date of grant. F1 · derivative.expiration_date: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on December 31, 2026. The options have a maximum term of ten (10) years from the date of grant. Read SEC document |
| December 20, 2024 Filed Dec 27, 2024 02:19 UTC | High Roller Technologies, Inc. ROLR · Entity 7043 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001753926-24-002152 · ownership.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-12-20 F1 · security: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on October 31, 2025. The options have a maximum term of ten (10) years from the date of grant. F1 · derivative.exercise_date: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on October 31, 2025. The options have a maximum term of ten (10) years from the date of grant. F1 · derivative.expiration_date: The options were granted pursuant to the High Roller Technologies, Inc. 2024 Equity Incentive Plan. The number of shares subject to the options shall vest and become exercisable on October 31, 2025. The options have a maximum term of ten (10) years from the date of grant. Read SEC document |
| August 15, 2023 Filed Aug 18, 2023 23:07 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-23-000885 · ownership.xml · nonDerivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,999 F1 · price: The shares of restricted stock were granted in lieu of remuneration for the Company's 2023 second quarter board fees and shall be fully vested as of August 15, 2023, the date of the grant, based on a closing price of $0.6364 per share on such date. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 20:33 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 17,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-23-000404 · ownership.xml · nonDerivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,999 F1 · price: The shares of restricted stock were granted in lieu of remuneration for the Company's 2023 first quarter board fees and shall be fully vested as of April 20, 2023, the date of the grant, based on a closing price of $1.32 per share on such date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:44 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-23-000176 · ownership.xml · nonDerivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,455 F1 · price: The shares of restricted stock were granted in lieu of remuneration for the Company's 2022 fourth quarter board fees and shall be fully vested as of February 24, 2023, the date of the grant, based on a closing price of $1.19 per share on such date. Read SEC document |
| November 18, 2022 Filed Nov 23, 2022 01:08 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 45,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-22-001353 · ownership.xml · nonDerivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,455 F1 · price: The shares of restricted stock were granted in lieu of remuneration for the Company's third quarter board meeting and shall be fully vested as of November 18, 2022, the date of the grant, based on a closing price of $0.44 per share. Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 21:20 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000497 · ownership.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:18 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001094891-21-000170 · edgar.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on September 30, 2021. Read SEC document |
| April 30, 2020 Filed May 4, 2020 22:08 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001094891-20-000080 · edgar.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-04-30 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on June 30, 2020. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 15:48 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001185185-20-000478 · ownership.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-04-14 F1 · derivative.exercise_date: The option vested in full on April 14, 2020. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 18:54 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 36,240 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001185185-19-001470 · ownership.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,240 Underlying: Common Stock · 36,240 shares Expires 2029-10-30 F1 · derivative.exercise_date: The option vested on October 30, 2019. Read SEC document |
| March 07, 2019 Filed Mar 12, 2019 01:17 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001094891-19-000084 · edgar.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on March 31, 2019. Read SEC document |
| October 16, 2018 Filed Nov 10, 2018 01:30 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 69,132 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001185185-18-001984 · ownership.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,132 Underlying: Common Stock · 69,132 shares Expires 2028-10-16 F1 · derivative.exercise_date: One-fourth (1/4) of the option vested on October 16, 2018 and the remainder will vest as follows: (i) one-fourth (1/4) will vest on January 1, 2019; (ii) one-fourth (1/4) will vest on January 1, 2020; and (iii) one-fourth (1/4) will vest on January 1, 2021. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:26 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001094891-18-000050 · edgar.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on March 31, 2018. Read SEC document |
| November 24, 2017 Filed Nov 29, 2017 02:01 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-002505 · form4-weild112817.xml · nonDerivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| December 22, 2016 Filed Feb 9, 2017 22:02 UTC | Streamex Corp. BSGM · Entity 1816 | GrantOptions to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001185185-17-000245 · form4-weild020917.xml · derivative · entry 1 Weild IV David · CIK 0001648023 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-12-22 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.